Neurological Soft Signs and Post-Traumatic Stress Disorder: A Biomarker of Severity?
cerebellum
gender
neurological soft signs
post-traumatic stress disorder (PTSD)
recovery
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
02
2020
accepted:
03
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
The psychophysiological changes for individual suffering from chronic post-traumatic stress disorder (PTSD) raise to the questions of how facilitate recovery and return to work. Negative alterations in neuro-cognition remain a complaint for patients and participate to long-term functional impairments. Neurological soft signs (NSSs) appear as a candidate for better understanding these complaints. They have been reported in several mental disorders. They are found in several behavioral and/or neurocognitive disorders and are taken into account by psychiatric rehabilitation programs to support recovery. As few studies evaluate NSSs in PTSD, our exploratory study aims to assess NSSs in chronic PTSD and their relationships with PTSD severity. Twenty-two patients with a clinical diagnosis of chronic PTSD were evaluated in terms of PTSD severity (post-traumatic checklist scale, PCL5), NSSs (NSSs psychomotor skills scale, PASS), and well-being upon arrival to the hospital and compared with 15 healthy subjects. Statistical non-parametric analyses assessed the relationships between these variables. PTSD subjects exhibited higher NSSs compared with healthy subjects. NSSs were positively associated with PTSD severity, with negative alterations in cognition and mood, and with impairment in well-being. They were higher in women compared with men. No impact of age was found. Three groups were identified based on the severity of the PTSD. Severe PTSD exhibited NSSs characterized by motor integration alterations. This pilot study suggests that NSSs might be a biomarker of PTSD severity. This proof of concept highlights the need for further research for better evaluating the clinical neuro-functional impairment. This will be helping for defining neurological remediation for promoting PTSD recovery.
Sections du résumé
BACKGROUND
BACKGROUND
The psychophysiological changes for individual suffering from chronic post-traumatic stress disorder (PTSD) raise to the questions of how facilitate recovery and return to work. Negative alterations in neuro-cognition remain a complaint for patients and participate to long-term functional impairments. Neurological soft signs (NSSs) appear as a candidate for better understanding these complaints. They have been reported in several mental disorders. They are found in several behavioral and/or neurocognitive disorders and are taken into account by psychiatric rehabilitation programs to support recovery. As few studies evaluate NSSs in PTSD, our exploratory study aims to assess NSSs in chronic PTSD and their relationships with PTSD severity.
METHOD
METHODS
Twenty-two patients with a clinical diagnosis of chronic PTSD were evaluated in terms of PTSD severity (post-traumatic checklist scale, PCL5), NSSs (NSSs psychomotor skills scale, PASS), and well-being upon arrival to the hospital and compared with 15 healthy subjects. Statistical non-parametric analyses assessed the relationships between these variables.
RESULTS
RESULTS
PTSD subjects exhibited higher NSSs compared with healthy subjects. NSSs were positively associated with PTSD severity, with negative alterations in cognition and mood, and with impairment in well-being. They were higher in women compared with men. No impact of age was found. Three groups were identified based on the severity of the PTSD. Severe PTSD exhibited NSSs characterized by motor integration alterations.
CONCLUSIONS
CONCLUSIONS
This pilot study suggests that NSSs might be a biomarker of PTSD severity. This proof of concept highlights the need for further research for better evaluating the clinical neuro-functional impairment. This will be helping for defining neurological remediation for promoting PTSD recovery.
Identifiants
pubmed: 33192652
doi: 10.3389/fpsyt.2020.533662
pmc: PMC7606651
doi:
Types de publication
Journal Article
Langues
eng
Pagination
533662Informations de copyright
Copyright © 2020 Belrose, Duffaud, Rakotoarison, Faget, Raynaud, Dutheil, Boyer, Billaud and Trousselard.
Références
J Affect Disord. 2015 Mar 15;174:336-41
pubmed: 25545601
Psychol Bull. 2000 May;126(3):424-53
pubmed: 10825784
Chronic Stress (Thousand Oaks). 2018 Jan-Dec;2:
pubmed: 30035247
Cogn Emot. 2017 Apr;31(3):598-606
pubmed: 26743908
Psychol Med. 1997 Jul;27(4):861-73
pubmed: 9234464
J Psychiatr Res. 2013 Jan;47(1):64-71
pubmed: 23107307
PLoS One. 2016 Oct 10;11(10):e0161645
pubmed: 27723815
Biol Psychiatry. 2001 Aug 15;50(4):246-53
pubmed: 11522258
Mol Psychiatry. 2014 Nov;19(11):1156-62
pubmed: 25245500
J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):16-28
pubmed: 21304135
Am J Psychiatry. 2002 Dec;159(12):2013-20
pubmed: 12450950
J Consult Clin Psychol. 1981 Dec;49(6):807-21
pubmed: 7309951
Neurosci Lett. 2015 Sep 14;604:173-7
pubmed: 26219987
Cereb Cortex. 2006 Aug;16(8):1225-31
pubmed: 16251504
Neurosci Biobehav Rev. 2015 Dec;59:83-91
pubmed: 26441374
Harv Rev Psychiatry. 2018 Mar/Apr;26(2):57-69
pubmed: 29016379
Eur J Psychotraumatol. 2015 Jan 19;6:26068
pubmed: 25604705
Neurology. 2014 Dec 9;83(24):2269-77
pubmed: 25391304
Psychiatry Res. 2016 Nov 30;245:282-290
pubmed: 27565700
Brain Res. 2010 Sep 24;1353:60-73
pubmed: 20647004
Cochrane Database Syst Rev. 2013 Dec 13;(12):CD003388
pubmed: 24338345
Am J Psychiatry. 1988 Jan;145(1):11-8
pubmed: 3276226
J Int Neuropsychol Soc. 2009 Nov;15(6):879-87
pubmed: 19703324
Elife. 2019 Aug 29;8:
pubmed: 31464686
Am Psychol. 2007 Feb-Mar;62(2):95-108
pubmed: 17324035
J Affect Disord. 2007 Nov;103(1-3):99-103
pubmed: 17367868
Neuroimage. 2006 Jul 1;31(3):1359-65
pubmed: 16513370
Schizophr Res. 2000 Jun 16;43(2-3):109-16
pubmed: 10858629
Am J Psychiatry. 2007 Jan;164(1):150-3
pubmed: 17202557
Psychiatry Res. 2002 May 15;110(1):81-5
pubmed: 12007596
Arch Gen Psychiatry. 2005 Jun;62(6):617-27
pubmed: 15939839
J Anxiety Disord. 2013 Aug;27(6):550-8
pubmed: 23422492
Dement Neuropsychol. 2012 Oct-Dec;6(4):203-211
pubmed: 29213799
Biol Mood Anxiety Disord. 2012 May 18;2:9
pubmed: 22738125
Schizophr Bull. 2010 Nov;36(6):1089-104
pubmed: 19377058
Eur J Psychotraumatol. 2017 Apr 11;8(1):1302652
pubmed: 28451068
Schizophr Bull. 2000;26(1):119-36
pubmed: 10755673
Health Psychol. 2012 Mar;31(2):194-201
pubmed: 22023435
J Anxiety Disord. 2013 Mar;27(2):188-96
pubmed: 23454838
Brain. 2006 Feb;129(Pt 2):290-2
pubmed: 16434422
Biol Psychiatry. 2006 Aug 15;60(4):376-82
pubmed: 16919525
Front Psychiatry. 2019 Jan 08;9:737
pubmed: 30670989
J Nerv Ment Dis. 2012 May;200(5):444-50
pubmed: 22551799
Neuroimage. 2009 May 15;46(1):39-46
pubmed: 19457380
Am J Psychiatry. 2006 Apr;163(4):659-66
pubmed: 16585441
J Womens Health (Larchmt). 2010 Feb;19(2):267-71
pubmed: 20109115
Neurosci Biobehav Rev. 2012 Oct;36(9):2130-42
pubmed: 22766141
Nat Rev Neurosci. 2012 Nov;13(11):769-87
pubmed: 23047775
Psychiatry Clin Neurosci. 2019 Apr;73(4):143-153
pubmed: 30653780
Schizophr Res Cogn. 2018 Dec 21;16:17-24
pubmed: 30671351
Intelligence. 2009 Mar 1;37(2):156-163
pubmed: 20160919
Neuropsychology. 2002 Jan;16(1):5-14
pubmed: 11853357
Curr Opin Psychol. 2017 Apr;14:72-77
pubmed: 28813323
Neuropsychopharmacology. 2019 Jan;44(1):71-85
pubmed: 29930385
Dev Psychol. 2018 Nov;54(11):2043-2052
pubmed: 30265034
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Front Neurosci. 2019 Mar 08;13:185
pubmed: 30906246
J Inflamm Res. 2018 Mar 22;11:111-121
pubmed: 29606885
Cerebellum. 2005;4(4):290-4
pubmed: 16321885
Neurosci Lett. 2006 May 8;398(3):189-94
pubmed: 16469446
Neuropharmacology. 2012 Feb;62(2):686-94
pubmed: 21349277
Hum Brain Mapp. 2017 Jan;38(1):541-560
pubmed: 27647695
Eur Arch Psychiatry Clin Neurosci. 2002 Apr;252(2):68-75
pubmed: 12111339
Arch Gen Psychiatry. 2000 Feb;57(2):181-6
pubmed: 10665621
Nat Rev Dis Primers. 2015 Oct 08;1:15057
pubmed: 27189040